This website is intended for Ireland Healthcare Professionals only. Not a Healthcare Professional in Ireland? Click here

VEOZA™ (fezolinetant) is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.1

VMS are also known as hot flushes and night sweats.2

Ms-A-card-image

Ms A

  • Hot flushes, night sweats
  • Breakthrough bleeding on HRT*
Ms-B-card-image

Ms B

  • Hot flushes, night sweats
  • On SNRI** (venlaflaxine)
Ms-C-card-image

Ms C

  • Unable to sleep due to night sweats. Hot flushes severely impacting daily life
  • Bleeding problems on HRT 
  • CV co-morbidities
Ms-E-card-image

Ms D

  • Hot flushes, night sweats, brain fog
  • Breakthrough bleeding on HRT
  • Progestogen sensitivity (low mood & bloating)
Ms-D-card-image

Ms E

  • Hot flushes, night sweats, low mood & sleep disturbance
  • Did not want SSRI*** as not depressed
  • Did not want HRT due to increased risk of blood clot due to Factor V Leiden homozygous status
Fast relief of hot flushes & night sweats.

Fast relief of hot flushes & night sweats. 1 dose a day, no titration.1,4

*HRT: hormone replacement therapy
**SNRI: serotonin & norepinephrine reuptake inhibitor
***SSRI: selective serotonin reuptake inhibitor

 

REFERENCES: 1. VEOZA Summary of Product Characteristics. 2. Thurston RC. Vasomotor symptoms. In: Crandall CJ, Bachman GA, Faubion SS, et al., eds. Menopause Practice: A Clinician’s Guide. 6th ed. Pepper Pike, OH: The North American Menopause Society, 2019:43-55. 3. VEOZA Patient Information Leaflet. 4. Data on file Data on File: ref 40499


Adverse events should be reported. For Ireland, Healthcare professionals are asked to report any suspected adverse reactions via: HPRA Pharmacovigilance, Website: www.hpra.ie or Astellas Pharma Co. Ltd. Tel:+353 1 467 1555, E-mail: irishdrugsafety@astellas.com.
 

MAT-IE-VEO-2025-00070 March 2026